PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A-Reference-Cited by-同舟云学术

PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A

Published:2021-03-16 Issue:3 Volume:27 Page:434-444
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Mancuso Maria Elisa¹²^ORCID,Biss Tina³,Fischer Kathelijn⁴^ORCID,Maas Enriquez Monika⁵,Steele MacGregor⁶,Wang Maria⁷,Tseneklidou‐Stoeter Despina⁸,Ahuja Sanjay⁹,Kenet Gili¹⁰^ORCID

Affiliation:

1. Fondazione IRCCS Ca’ GrandaOspedale Maggiore Policlinico Milan Italy

2. Center for Thrombosis and Hemorrhagic Diseases IRCCS Humanitas Research Hospital Milan Italy

3. Newcastle upon Tyne Hospitals NHS Foundation Trust Newcastle upon Tyne UK

4. Van Creveldkliniek University Medical Center UtrechtUtrecht University Utrecht The Netherlands

5. Bayer Wuppertal Germany

6. Cumming School of Medicine Alberta Children's Hospital University of Calgary Calgary AB Canada

7. Bayer Whippany NJ USA

8. Bayer Berlin Germany

9. Rainbow Hemostasis & Thrombosis Center University Hospitals Rainbow Babies and Children's HospitalCase Western Reserve University School of Medicine Cleveland OH USA

10. Israel National Hemophilia Center Chaim Sheba Medical Center Tel Hashomer Israel & The Amalia Biron Thrombosis Research InstituteTel Aviv University Tel Aviv Israel

Funder

Bayer

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14294

Reference16 articles.

1. Novel therapies and current clinical progress in hemophilia A

2. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males

3. WFH Guidelines for the Management of Hemophilia, 3rd edition